No silver bullet, but precision oncology can help doctors hit the target
In the run up to the annual meeting of the American Society of Clinical Oncology, we present the first of three analyses focusing on the state of cancer research and care. This week, our correspondent reviews progress in the much-anticipated field of precision oncology.
In January 2015, when then-US president Barack Obama launched the Precision Medicine Initiative he announced: “The dawn of a new era has arrived,” adding that the new approach “gives us one of the greatest opportunities for new medical breakthroughs we have ever seen.”
Two years on, such rhetoric may appear a little overblown. For some, precision oncology is a promise that keeps being made, with little being delivered.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze